ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.446,94
-0,03%
S&P 500
6.101,24
-0,29%
US Dollar vs BRL
5,91319
0,00%
Bitcoin
104.950,87
0,09%
Brent Oil
77,625
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Zevra Therapeutics Inc (ZVRA)

  7. Zevra Therapeutics Inc (ZVRA) Notícias

ZVRA

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ZVRA
DataHoraFonteTítuloCódigoCompanhia
17/12/202409:30GlobeNewswire Inc.Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024NASDAQ:ZVRAZevra Therapeutics Inc
06/12/202419:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
06/12/202419:00GlobeNewswire Inc.Zevra Therapeutics Announces Organizational ChangesNASDAQ:ZVRAZevra Therapeutics Inc
26/11/202409:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
21/11/202418:51GlobeNewswire Inc.Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
14/11/202418:53Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ZVRAZevra Therapeutics Inc
14/11/202415:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ZVRAZevra Therapeutics Inc
13/11/202418:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
12/11/202418:05GlobeNewswire Inc.Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
11/11/202418:36GlobeNewswire Inc.Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
06/11/202409:30GlobeNewswire Inc.Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13NASDAQ:ZVRAZevra Therapeutics Inc
31/10/202408:30GlobeNewswire Inc.Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024NASDAQ:ZVRAZevra Therapeutics Inc
16/10/202417:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
10/10/202408:30GlobeNewswire Inc.Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCNASDAQ:ZVRAZevra Therapeutics Inc
09/10/202410:00GlobeNewswire Inc.NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
24/09/202408:30GlobeNewswire Inc.Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024NASDAQ:ZVRAZevra Therapeutics Inc
20/09/202413:08GlobeNewswire Inc.Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
06/09/202409:30GlobeNewswire Inc.Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumNASDAQ:ZVRAZevra Therapeutics Inc
13/08/202417:05GlobeNewswire Inc.Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:ZVRAZevra Therapeutics Inc
13/08/202406:45IH Market NewsU.S. Futures Climb Before Inflation Data; Oil Slips on OPEC Demand CutNASDAQ:ZVRAZevra Therapeutics Inc
09/08/202417:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVRAZevra Therapeutics Inc
09/08/202401:00GlobeNewswire Inc.Zevra Therapeutics Announces Pricing of Underwritten Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
08/08/202417:01GlobeNewswire Inc.Zevra Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
07/08/202410:34GlobeNewswire Inc.Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
02/08/202418:50GlobeNewswire Inc.FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
30/07/202409:38GlobeNewswire Inc.Zevra Therapeutics to Report Second Quarter 2024 Financial ResultsNASDAQ:ZVRAZevra Therapeutics Inc
12/07/202417:23Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:ZVRAZevra Therapeutics Inc
09/07/202410:00GlobeNewswire Inc.Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
25/06/202408:30GlobeNewswire Inc.Zevra Therapeutics Expands Executive Leadership TeamNASDAQ:ZVRAZevra Therapeutics Inc
18/06/202408:30GlobeNewswire Inc.Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ZVRA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
GFSA3
GAFISA ON
BOV
RCSL4
RECRUSUL PN
BOV
AZEV4
AZEVEDO PN
BOV
PRIO3
PETRORIO ON
BOV
COGN3
COGNA ON
BOV
FICT3
Fictor Alimentos ON
BOV
IRBR3
IRB BRASIL ON
BOV
AMER3
Americanas ON
BOV
PMAM3
PARANAPANEMA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados